Scarica l'app Stockscreener
7.59
0.26%
0.02
Pre-mercato:
7.57
-0.02
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings - MarketBeat
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance
FDA extends Orladeyo approval to children as young as 2 - Angioedema News
BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval By Investing.com - Investing.com Nigeria
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - sharewise.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst wins FDA approval for Orladeyo oral pellets - MSN
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com
BioCryst’s Orladeyo wins expanded FDA approval - The Pharma Letter
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug - Benzinga
BioCryst Announces Board Chair Transition Plan - TipRanks
FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema - Contemporary Pediatrics
Sector Update: Health Care Stocks Edge Higher Premarket Friday - marketscreener.com
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits
BioCryst stock rises after FDA approves ORLADEYO oral pellets for children - Investing.com Canada
FDA Approves BioCryst's (BCRX) Oral Pellet Formulation of Orlade - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children - Investing.com
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
FDA Gives Green Light to BioCryst's (BCRX) ORLADEYO for Pediatri - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals Announces FDA Approval of ORLADEYO Oral Pellets as First Targeted Prophylactic Therapy for Pediatric Patients with HAE Aged 2 and Older - Quiver Quantitative
FDA expands approval of BioCryst's rare disease drug for use in young children - marketscreener.com
BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan
Nebula Research & Development LLC Invests $2.57 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight - The Globe and Mail
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - moha.gov.vn
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How BioCryst Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
BioCryst receives antitrust clearance for Astria acquisition By Investing.com - Investing.com Canada
3.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):